Evidence Table M3: DISCRETE outcomes for class ANTI-ANDROGEN.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	M.01.02			**Cyproterone + ethinyl estradiol**	**Minocycline hydrochloride**	
245 ↓ Parallel Mild/mod N=98		**GI+other side effects**		Heartburn/ depression 0 Diarrhea 0 Nausea/vomiting/giddness 2 Bleeding problems 4	Heartburn/ depression 4 Diarrhea 4 Nausea/vomiting/giddness 3 Bleeding problems 1	**NS**
		Gyn side effects		Headaches 4 White vaginal discharge 1 Weight gain 5 Painful/swollen breasts 3 Vaginal irritation 0	Headaches 3 White vaginal discharge 0 Weight gain 1 Painful/swollen breasts 0 Vaginal irritation 1	**NS**
		Skin side effects		Headaches/giddness/fluid retention 1 Dry skin 1 Spider nevus on nose 1 Hair falling out 0 Itching 0	Headaches/giddiness/fluid retention 0 Dry skin 0 Spider nevus on nose 0 Hair falling out 1 Itching 1	**NS**
		Overall change/patient	Long (24	Anxiety, depression Some improvement 36 Complete improvement 7 Other 6	Anxiety, depression Some improvement 34 Complete improvement 8 Other 7	**NS**
	M.01.03			**Cyproterone + ethinyl estradiol + placebo**	**Tetracycline + placebo**	
137 ↑ Parallel N=92		**Systemic reactions**	Long (24	Chest pain 0 Headache 0 Menstrual irregularity 0 Breast tenderness 0	Chest pain 0 Headache 0 Menstrual irregularity 0 Breast tenderness 0	
				Hypertension 1 Dysmenorrhoea 1	Hypertension 0 Dysmenorrhoea 0	
	M.01.05			**Cyproterone + ethinyl estradiol (0.05)**	**Levonorgestrel + ethinyl estradiol (0.030)**	
48 ↑ Parallel N=133		**Discontinuation due to side effects**		Discontinuation 5	Discontinuation 6	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
48 ↑ Parallel N=133		**Total lesions change** Between P-value: vs levonorgestrel	Long (24	> 75% reduction 30 No change or worse 2 Else (total-1-2) 13	>75% reduction 9 No change or worse 6 Else (total-1-2) 21	**0.001**
	M.01.07			**Cyproterone + ethinyl estradiol (0.035)**	**Desogestrel + ethinyl estradiol**	
103 ↓ Parallel N=162		**Back improvement**	Mid (12)	Yes 41 No 38	Yes 38 No 45	**NS**
		Chest improvement	Mid (12)	Yes 43 No 36	Yes 42 No 41	**NS**
		Complete healing	Mid (12)	Yes 28 No 51	Yes 20 No 63	
		Face improvement	Mid (12)	Yes 46 No 33	Yes 32 No 51	**0.05**
		Back improvement	Long (32	Yes 66 No 13	Yes 68 No 15	**NS**
		Chest improvement	Long (32	Yes 68 No 11	Yes 65 No 18	**NS**
		Complete healing	Long (32	Yes 46 No 33	Yes 62 No 21	
		Face improvement	Long (32	Yes 64 No 15	Yes 52 No 31	**0.05**
		Side effects	Long (32	Headache 75 Reduced libido 5 Breast tenderness 19 Nervousness 21	Headache 76 Reduced libido 29 Breast tenderness 58 Nervousness 48	**0.05**
				Depression 9 Edema 29	Depression 45 Edema 22	
	M.01.08			**Cyproterone + ethinyl estradiol (0.035)**	**Levonorgestrel + ethinyl estradiol (0.030)**	
48 ↑ Parallel N=133		**Discontinuation due to side effects**		Discontinuation 6	Discontinuation 6	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
48 ↑ Parallel N=133		**Total lesions change** Between P-value: vs levonorgestrel	Long (24	>75% reduction 27 No change or worse 2 Else (total-1-2) 15	>75% reduction 9 No change or worse 6 Else (total-1-2) 21	**0.001**
	M.01.09			**Cyproterone (.05 mg) + ethinyl estradiol**	**Norethisterone + placebo + ethinyl estradiol**	
237 Parallel Mod/sev N=90		**Systemic reactions I > once**	Long (26	Tiredness/lassitude 3 Loss of libido 1 Headaches 3 Dizziness/ giddiness 0	Tiredness/lassitude 4 Loss of libido 0 Headaches 3 Dizziness/ giddiness 1	
				Breast soreness 2 Urinary urgency 1 depression 1 Nausea/vomiting 2	Breast soreness 2 Urinary urgency 0 Depression 1 Nausea/vomiting 2	
		Systemic reactions I once only	Long (26	Tiredness/lassitude 1 Loss of libido 1 Headaches 4 Dizziness/giddiness 4	Tiredness/lassitude 1 Loss of libido 1 Headaches 2 Dizziness/giddiness 3	
				Breast soreness 4 Urinary urgency 3 depression 3 Nausea/vomiting 2	Breast soreness 3 Urinary urgency 3 Depression 3 Nausea/vomiting 6	
		Systemic reactions II > once	Long (26	Abnormal uterine bleeding 1 Aching legs 0 Consipation 0 Abdominal pain 0	Abnormal uterine bleeding 0 Aching legs 0 Consipation 0 Abdominal pain 0	
				Benign breast tomor 0 Vaginal discharge 0	Benign breast tomor 0 Vaginal discharge 0	
		Systemic reactions II once only	Long (26	Abnormal uterine bleeding 4 Aching legs 3 Constipation 0 Abdominal pain 0	Abnormal uterine bleeding 3 Aching legs 1 Constipation 3 Abdominal pain 0	
				Benign breast tumor 0 Vaginal discharge 0	Benign breast tumor 0 Vaginal discharge 0	
	M.02.01			**Desogestrel + ethinyl estradiol**	**Gestodene + ethinyl estradiol**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
225 ↓ Parallel Mild/mod N=24		**Severity (pillsbury)**	Mid (12)	Absent 0 Minimal 3 Minor 2 Mild 6 Moderate 0	Absent 1 Minimal 1 Minor 2 Mild 4 Moderate 0	
		Severity change (pillsbury)	Long (36	Absent 2 Minimal 8 Minor 1 Mild 0 Moderate 0	Absent 3 Minimal 2 Minor 1 Mild 2 Moderate 0	
		Systemic adverse effects	Long (36	Present 6 Absent 5	Present 4 Absent 4	
	M.02.02			**Desogestrel + ethinyl estradiol**	**Levonorgestrel + ethinyl estradiol**	
263 Parallel N=54		**Side effects**		Worse acne & drop out 2 Irregular bleed 2	Worse acne & drop out 4 Irregular bleed 3	
		Severity change	Long (24	Improved 9 No improvement 1	Improved 5 No improvement 4	**0.05**
	M.03.01			**Spironolactone**	**Placebo**	
249 ↑ Cross-over Mild/mod N=58		**Change (count)**	Mid (12)	Improved 15 Unchanged 5 Worse 0	Improved 4 Unchanged 9 Worse 7	**0.001**
		Overall change/patient	Mid (12)	Proportion improved 18 Proportion unchanged 3 Proportion worse 0	Proportion improved 5 Proportion unchanged 9 Proportion worse 7	**0.001**
		Positive side effects	Mid (12)	Decreased oily skin 9 Breast enlargement 2	Decreased oily skin 0 Breast enlargement 0	
		Severity/photo	Mid (12)	Improved 11 Unchanged 7 Worse 1	Improved 4 Unchanged 12 Worse 3	**0.02**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
249 ↑ Cross-over Mild/mod N=58		**Side effects**	Mid (12)	Menstrual irregularity 11 Severe nausea (drop out) 2 Nausea 1 Dizziness 1	Menstrual irregularity 0 Severe nausea (drop out) 0 Nausea 0 Dizziness 0	
	M.04.01			**Delta-0.2%-chlormadione**	**Vehicle**	
2 ↑ Parallel split face N=20		**Overall change/patient**	Mid (7)	Change in acne 0 No change in acne 10	Change in acne 0 No change in acne 20	
		Overall change/physician	Mid (7)	Change in acne 0 No change in acne 10	Change in acne 0 No change in acne 20	
	M.04.02			**Delta-5%-chlormadione**	**Vehicle**	
2 ↑ Parallel split face N=20		**Overall change/patient**	Mid (7)	Change in acne 0 No change in acne 10	Change in acne 0 No change in acne 20	
		Overall change/physician	Mid (7)	Change in acne 0 No change in acne 10	Change in acne 0 No change in acne 20	
	M.04.03			**Delta-0.2%-chlormadione**	**Delta-5%-chlormadione**	
2 ↑ Parallel split face N=20		**Overall change/patient**	Mid (7)	Change in acne 0 No change in acne 10	Change in acne 0 No change in acne 10	
		Overall change/physician	Mid (7)	Change in acne 0 No change in acne 10	Change in acne 0 No change in acne 10	
	M.04.04			**16-epiestriol-3-allyl ether**	**Placebo**	
19 Parallel N=134		**Oiliness**	Mid (12)	No change 30 Improved 19 Marked improvement 17	No change 35 Improved 24 Marked improvement 9	**NS**
		Severity change	Mid (12)	No change 31 Improved 19 Marked improvement 16	No change 34 Improved 26 Marked improvement 8	**NS**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	M.04.05			**Epiestriol**	**Vehicle**	
295 ↑ Parallel split face N=50		**Inter-treatment severity change**	Mid (12)	Better 9 Same 23	Better 23 Same 8	
		Overall change/physician	Mid (12)	Worse 7 Unchanged 18 Improved 19	Worse 7 Unchanged 18 Improved 19	
	M.04.06			**Inocoterone acetate**	**Vehicle**	
213 ↑ Parallel Mod N=153		**Local adverse reactions**		Burning 32 Stinging 18 Itching 10 Redness 19	Burning 24 Stinging 24 Itching 6 Redness 15	**NS**
				Peeling 27	Peeling 12	
	M.04.09			**Norgestimate + ethinyl estradiol + inactive drug**	**Placebo**	
218 ↑ Parallel Mod N=257		**Overall change/investigator**	Long (26	Excellent 30 Good 28 Fair 16 No change 3	Excellent 15 Good 24 Fair 14 No change 20	**0.001**
				Worse 2	Worse 8	
		Overall change/patient	Long (26	Much improved 34 Somewhat improved 39 Not improved 5 Worse 1	Much improved 18 Somewhat improved 40 Not improved 19 Worse 4	**0.001**
280 ↑ Parallel Mod N=250		**Adverse events**		Discontinued therapy 13 Other 113	Discontinued therapy 5 Other 119	
		Overall change/investigator	Long (24	Excellent 22 Good 32 Fair 16 No change 9	Excellent 6 Good 25 Fair 19 No change 25	**0.001**
				Worse 5	Worse 5	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
280 ↑ Parallel Mod N=250		**Overall change/patient**	Long (24	Much improved 30 Somewhat improved 38 Not improved 10 Worse 5	Much improved 10 Somewhat improved 28 Not improved 37 Worse 5	**0.001**
				Much worse 0	Much worse 0	
	M.04.11			**Serum gonadotrophin**	**Placebo**	
271 ↑ Parallel Mild/mod/sev N=40		**Overall change/patient with physician**	Mid (12)	Improved 8 No change 9 Worse 2	Improved 9 No change 9 Worse 3	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.